Lv42
548 积分 2022-10-24 加入
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
7天前
已完结
A shifting market environment and strategies fueling innovation in prostate cancer treatment
1个月前
已完结
Osteosarcoma
1个月前
已关闭
Balancing weight and muscle loss in GLP1 receptor agonist therapy
1个月前
已完结
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer
1个月前
已完结
Prostate cancer epigenetics — from pathophysiology to clinical application
1个月前
已完结
Prostate cancer epigenetics — from pathophysiology to clinical application
1个月前
已关闭
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
1个月前
已完结
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
1个月前
已完结
Personalized intensification of treatment for hormone-sensitive prostate cancer
1个月前
已完结
Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers
皖公网安备34019202002308
